Refine
Year of publication
Language
- English (170) (remove)
Has Fulltext
- yes (170)
Is part of the Bibliography
- no (170)
Keywords
- LHC (7)
- breast cancer (7)
- Mammakarzinom (6)
- Behandlung (4)
- Breast cancer (4)
- Metastasen (4)
- ALICE (3)
- ALICE experiment (3)
- CDK4/6 (3)
- Hadron-Hadron Scattering (3)
- PD1/PDL1 (3)
- Prävention (3)
- Studien (3)
- pp collisions (3)
- prevention (3)
- treatment (3)
- Beauty production (2)
- Clinical Trials and Observations (2)
- Radiotherapy (2)
- Risiko (2)
- Single electrons (2)
- lapatinib (2)
- lymphocytes (2)
- metastases (2)
- metastatic (2)
- neoadjuvant therapy (2)
- presenilin-1 (2)
- risk (2)
- trastuzumab (2)
- trials (2)
- 3′UTR length (1)
- 900 GeV (1)
- AD patients (1)
- APA (1)
- Acetogen (1)
- Acetogenesis (1)
- Advanced breast cancer (1)
- Alpelisib (1)
- Alzheimer's disease (1)
- Alzheimer’s disease (1)
- Anandamide (1)
- Animal models (1)
- Antihormone therapy (1)
- Artificial Intelligence (1)
- Atezolizumab (1)
- B cell malignancies (1)
- BCOR (1)
- BCORL1 (1)
- Biodiversity Data (1)
- Biomonitoring (1)
- Bone metastases (1)
- Borderline personality disorder (1)
- Botanical Collections (1)
- Brain metastasis (1)
- Brain tumors (1)
- C3M (1)
- C4M (1)
- CCL2 (1)
- CFIm (1)
- COVID (1)
- COVID-19 (1)
- CRISPR/Cas (1)
- CRM1 (1)
- CVID (1)
- Cancer (1)
- Cancer treatment (1)
- Central nervous system metastases (1)
- Charm physics (1)
- Childhood abuse (1)
- Children and adolescents (1)
- Chromatin (1)
- Clinical variation (1)
- Cold hardiness (1)
- Cold tolerance (1)
- Compact astrophysical objects (1)
- Comparison with QCD (1)
- Complex posttraumatic stress disorder (1)
- Compression stocking (1)
- Conservation (1)
- DNA damage (1)
- Deep vein thrombosis (1)
- Diagnostik (1)
- Dialectical behavioural therapy (1)
- Digitization (1)
- Distribution limits (1)
- E. coli (1)
- EGFR (1)
- EP300 (1)
- EWSR1 (1)
- Elderly (1)
- Emotion (1)
- European Society for Immunodeficiencies (ESID) (1)
- Exosomes (1)
- FIP1 (1)
- FOXO1 (1)
- Femtoscopy (1)
- First site of metastatic disease (1)
- Flightless-I (1)
- Frailty (1)
- Früherkennung (1)
- G-quadruplexes (1)
- Galaktografie (1)
- Galaktomosynthese (1)
- Galaxies and clusters (1)
- Gene fusion (1)
- Gene regulation (1)
- General practitioners (1)
- Genome editing (1)
- German PID-NET registry (1)
- Glutathione reductase (1)
- HBT (1)
- HDAC4 (1)
- HER2 c-erbB2 (1)
- HER2-positive (1)
- HER2/neu (1)
- HOX gene (1)
- Hadron production (1)
- Head and neck cancer (1)
- Heavy Ions (1)
- Heavy flavor production (1)
- Heavy flavour production (1)
- Heavy ions (1)
- Heavy-flavour production (1)
- Heavy-ion collisions (1)
- Herbaria (1)
- Heregulin (1)
- High-energy astrophysics (1)
- Hypertension (1)
- IgG substitution therapy (1)
- Inclusive spectra (1)
- Inflammation (1)
- Intensity interferometry (1)
- Jets (1)
- KCGS (1)
- Katherine (1)
- Lesions (1)
- Leukemia (1)
- Lipid peroxidation (1)
- Lokalrezidiv (1)
- Lymphoid Neoplasia (1)
- MACE-seq (1)
- MEIS2 (1)
- MLL1/2 (1)
- MM-121 (1)
- MRI (1)
- MRT (1)
- Machine learning (1)
- Mamma (1)
- Mesenchymal stem cells (1)
- MetVF (1)
- Meta-analysis (1)
- Metastatic (1)
- Methylene-tetrahydrofolate reductase (1)
- MicroRNAs (1)
- Mid-rapidity (1)
- Molecular subtypes (1)
- Multi-strange baryons (1)
- Myeloid Neoplasia (1)
- NCoR1 (1)
- NMR spectroscopy (1)
- Nachsorge (1)
- Nanoscale materials (1)
- Necrosis (1)
- Neoadjuvant therapy (1)
- Neural signature (1)
- Neuroepithelial tumor (1)
- Non-small cell lung cancer (1)
- Nuclear modification factor (1)
- Oldest-old (1)
- Overwintering (1)
- PARP (1)
- PBX1 (1)
- PD1/ PDL1 (1)
- PD‑L1 (1)
- PI3K (1)
- PID prevalence (1)
- PLAGL1 (1)
- PYTHIA (1)
- Pathological complete response (1)
- Patient reported outcomes (1)
- Patterns of care (1)
- Pb–Pb (1)
- Phenotypic plasticity (1)
- Post-traumatic stress disorder (1)
- Presenilin (1)
- Prognosefaktoren (1)
- Proton–proton (1)
- Prädiktivfaktoren (1)
- Pulmonary embolism (1)
- RBC (1)
- Radiation Oncology (1)
- Randomised controlled trial (1)
- Reactive oxygen species (1)
- Real-time polymerase chain reaction (PCR) tests (1)
- Red blood cell transfusion (1)
- Relativistic heavy ion physics (1)
- Research Infrastructure (1)
- Richtlinie (1)
- SARS-CoV-2 testing (1)
- SILAC-based proteomics (1)
- SRSF3 (1)
- SRSF7 (1)
- Salivary gland carcinoma (1)
- Sarcomas (1)
- Semantics (1)
- Seribantumab (1)
- Single muons (1)
- Social participation (1)
- Stereotactic radiosurgery (1)
- Sub-zero exposure (1)
- Sumoylation (1)
- Superoxide dismutase (1)
- Supportivtherapie (1)
- Supratentorial (1)
- Surgery (1)
- T-DM1 (1)
- TALE-homdomain protein (1)
- TERRA RNA (1)
- TGFB-induced factor homeobox 1 (1)
- TGIF (1)
- TKI (1)
- Taxonomy (1)
- Tomosynthese (1)
- Toxicity (1)
- Transverse momentum (1)
- Triple negative (1)
- Tumor heterogeneity (1)
- T‑DM1 (1)
- Ultraschall (1)
- Venous thromboembolism (1)
- Winter survival (1)
- Wood-Ljungdahl pathway (1)
- X-ray diffraction (1)
- accident (1)
- acute coronary syndrome (1)
- acute myeloid leukaemia (1)
- acute myeloid leukemia (1)
- adjuvant therapy (1)
- adjuvante Therapie (1)
- advanced (1)
- advanced breast cancer (1)
- alpelisib (1)
- amino acids (1)
- amyloid precursor protein (APP) (1)
- anaemia (1)
- anti-neural autoantibodies (1)
- antibiotic therapy (1)
- antibodies (1)
- antihormone therapy (1)
- apoptosis (1)
- archeological modeling (1)
- ascites (1)
- at-risk mental state (1)
- atezolizumab (1)
- autoimmune encephalitis (1)
- autoimmune-mediated psychosis (1)
- b-cell lymphomas (1)
- bendamustine (1)
- biophysics (1)
- breast (1)
- calcium (1)
- cancer (1)
- cell biology (1)
- cell death (1)
- channelrhodopsin (1)
- chemogenomic set (1)
- chemotherapy (1)
- chemotherapy regimen (1)
- chimeric antigen receptor t-cell therapy (1)
- chimeric antigen receptors (1)
- clinical high at-risk mental state (1)
- collagen degradation marker (1)
- conformational changes (1)
- controlled nuclear import (1)
- copeptin (1)
- cytochrome c. (1)
- dPAS (1)
- diagnosis (1)
- diffusion-weighted magnetic resonance imaging (1)
- drug discovery (1)
- druggable genome (1)
- early breast cancer (1)
- elderly patients (1)
- electron cryo-microscopy (1)
- folding landscapes (1)
- follow‑up (1)
- fortgeschritten (1)
- frühes Mammakarzinom (1)
- galactography (1)
- galactomosynthesis (1)
- guideline (1)
- head and neck cancer (1)
- healthy control (1)
- hematopoietic stem cell transplantation (1)
- human–environment interaction (1)
- iCLIP (1)
- image-based risk modelling (1)
- immune-checkpoint inhibition (1)
- induction chemotherapy (1)
- injury (1)
- kinase inhibitor (1)
- kinetically trapped state (1)
- kinetics (1)
- leukapheresis (1)
- light-gated ion channel (1)
- liver cirrhosis (1)
- local recurrence (1)
- lockdown (1)
- loss-of-function (1)
- lymphoma (1)
- mTOR (1)
- machine learning (1)
- metastasis (1)
- microbial rhodopsin (1)
- mortality (1)
- mouse (1)
- multidrug resistance (1)
- multiplexed immunofluorescence (1)
- myocardial infarction (1)
- neoadjuvant chemoradiotherapy (1)
- neoadjuvante Therapie (1)
- neurogenesis (1)
- neuroimaging (1)
- oocytes (1)
- open science (1)
- oral cavity cancer (1)
- oxidative stress (1)
- p63 (1)
- pPAS (1)
- paleoclimate modeling (1)
- paleoenvironment modeling (1)
- paleoenvironment reconstruction (1)
- pancreatic cancer (1)
- pediatric intensive care (1)
- personalised therapy (1)
- pertuzumab (1)
- phenotypic screening (1)
- posttranslational modification (1)
- predictive biomarker (1)
- predictive factors (1)
- primary immunodeficiency (PID) (1)
- prognostic factors (1)
- protein kinase (1)
- proteins (1)
- quality control (1)
- radiation oncology (1)
- radiomic (1)
- real-time NMR spectroscopy (1)
- registry (1)
- registry for primary immunodeficiency (1)
- risk stratification (1)
- rituximab (1)
- schizophrenia (1)
- screening (1)
- screening routine (1)
- small molecules (1)
- spectra (1)
- spring-loaded activation (1)
- stem cell niche (1)
- structural biolog (1)
- structure elucidation (1)
- studies (1)
- subventricular zone (1)
- supportive therapy (1)
- surgery (1)
- survival (1)
- targeted therapy (1)
- tomosynthesis (1)
- transfusion (1)
- transgenic mice (1)
- trauma (1)
- treatment/therapy (1)
- troponin (1)
- ultra-high risk for psychosis (1)
- ultrasound (1)
- understudied kinase (1)
- √sN N = 2.76 TeV (1)
Institute
- Physik (84)
- Frankfurt Institute for Advanced Studies (FIAS) (69)
- Informatik (68)
- Medizin (61)
- Biowissenschaften (6)
- Biochemie und Chemie (5)
- Georg-Speyer-Haus (5)
- Pharmazie (5)
- Geowissenschaften (4)
- Psychologie (3)
Introduction: Recommendations for venous thromboembolism and deep venous thrombosis (DVT) prophylaxis using graduated compression stockings (GCS) is historically based and has been critically examined in current publications. Existing guidelines are inconclusive as to recommend the general use of GCS.
Patients/Methods: 24 273 in-patients (general surgery and orthopedic patients) undergoing surgery between 2006 and 2016 were included in a retrospectively analysis from a single center. From January 2006 to January 2011 perioperative GCS was employed additionally to drug prophylaxis and from February 2011 to March 2016 patients received drug prophylaxis alone. According to german guidelines all patients received venous thromboembolism prophylaxis with weight-adapted LMWH. Risk stratification (low risk, moderate risk, high risk) was based on the guideline of the American College of Chest Physicians. Data analysis was performed before and after propensity matching (PM). The defined primary endpoint was the incidence of symptomatic or fatal pulmonary embolism (PE). A secondary endpoint was the incidence of deep venous thromboembolism (DVT).
Results: After risk stratification (low risk n = 16 483; moderate risk n = 4464; high risk n = 3326) a total of 24 273 patient were analyzed. Before to PM the relative risk for the occurrence of a PE or DVT was not increased by abstaining from GCS. After PM two groups of 11 312 patients each, one with and one without GCS application, were formed. When comparing the two groups, the relative risk (RR) for the occurrence of a pulmonary embolism was: Low Risk 0.99 [CI95% 0.998–1.000]; Moderate Risk 0.999 [CI95% 0.95–1.003]; High Risk 0.996 [CI95% 0.992–1.000] (p > 0.05). The incidence of PE in the total group LMWH alone was 0.1% (n = 16). In the total group using LMWH + GCS, the incidence was 0.3% (n = 29). RR after PM was 0.999 [CI95% 0.998–1.00].
Conclusion: In comparison to prior studies with only small numbers of patients our trial shows in a large group of patients with moderate and high risk developing VTE we can support the view that abstaining from GCS-use does not increase the incidence of symptomatic or fatal PE and symptomatic DVT.
Combinatorial CRISPR-Cas screens have advanced the mapping of genetic interactions, but their experimental scale limits the number of targetable gene combinations. Here, we describe 3Cs multiplexing, a rapid and scalable method to generate highly diverse and uniformly distributed combinatorial CRISPR libraries. We demonstrate that the library distribution skew is the critical determinant of its required screening coverage. By circumventing iterative cloning of PCR-amplified oligonucleotides, 3Cs multiplexing facilitates the generation of combinatorial CRISPR libraries with low distribution skews. We show that combinatorial 3Cs libraries can be screened with minimal coverages, reducing associated efforts and costs at least 10-fold. We apply a 3Cs multiplexing library targeting 12,736 autophagy gene combinations with 247,032 paired gRNAs in viability and reporter-based enrichment screens. In the viability screen, we identify, among others, the synthetic lethal WDR45B-PIK3R4 and the proliferation-enhancing ATG7-KEAP1 genetic interactions. In the reporter-based screen, we identify over 1,570 essential genetic interactions for autophagy flux, including interactions among paralogous genes, namely ATG2A-ATG2B, GABARAP-MAP1LC3B and GABARAP-GABARAPL2. However, we only observe few genetic interactions within paralogous gene families of more than two members, indicating functional compensation between them. This work establishes 3Cs multiplexing as a platform for genetic interaction screens at scale.
Poster presentation: Background Maraviroc is a new drug used to treat HIV infection from the new class of drugs called CCR5 entry inhibitors. As the active principle of these drugs is to block the CCR5-receptor on the surface of the target cells, it has to be known if the virus in the patient is using only CCR5 as co-receptor or if there are populations that can also use CXCR4. Therefore, an assay to determine the tropism has to be performed before starting a therapy. Besides phenotypic assays like the TROFILE® assay by Monogram, used in the approval studies, there exist several genotyping systems like geno2pheno-coreceptor, Wetcat (providing five different genotypic tropism schemes) and WebPSSM. ...
Chronic granulomatous disease (CGD) is a primary immunodeficiency characterized by impaired antimicrobial activity in phagocytic cells. As a monogenic disease affecting the hematopoietic system, CGD is amenable to gene therapy. Indeed in a phase I/II clinical trial, we demonstrated a transient resolution of bacterial and fungal infections. However, the therapeutic benefit was compromised by the occurrence of clonal dominance and malignant transformation demanding alternative vectors with equal efficacy but safety-improved features. In this work we have developed and tested a self-inactivating (SIN) gammaretroviral vector (SINfes.gp91s) containing a codon-optimized transgene (gp91(phox)) under the transcriptional control of a myeloid promoter for the gene therapy of the X-linked form of CGD (X-CGD). Gene-corrected cells protected X-CGD mice from Aspergillus fumigatus challenge at low vector copy numbers. Moreover, the SINfes.gp91s vector generates substantial amounts of superoxide in human cells transplanted into immunodeficient mice. In vitro genotoxicity assays and longitudinal high-throughput integration site analysis in transplanted mice comprising primary and secondary animals for 11 months revealed a safe integration site profile with no signs of clonal dominance.
Comprehensive analysis of tumour sub-volumes for radiomic risk modelling in locally advanced HNSCC
(2020)
Simple Summary: Radiomic risk models are usually based on imaging features, which are extracted from the entire gross tumour volume (GTV entire ). This approach does not explicitly consider the complex biological structure of the tumours. Therefore, in this retrospective study, we investigated the prognostic value of radiomic analyses based on different tumour sub-volumes using computed tomography imaging of patients with locally advanced head and neck squamous cell carcinoma who were treated with primary radio-chemotherapy. The GTV entire was cropped by different margins to define the rim and corresponding core sub-volumes of the tumour. Furthermore, the best performing tumour rim sub-volume was extended into surrounding tissue with different margins. As a result, the models based on the 5 mm tumour rim and on the 3 mm extended rim sub-volume showed an improved performance compared to models based on the corresponding tumour core. This indicates that the consideration of tumour sub-volumes may help to improve radiomic risk models.
Abstract: Imaging features for radiomic analyses are commonly calculated from the entire gross tumour volume (GTVentire). However, tumours are biologically complex and the consideration of different tumour regions in radiomic models may lead to an improved outcome prediction. Therefore, we investigated the prognostic value of radiomic analyses based on different tumour sub-volumes using computed tomography imaging of patients with locally advanced head and neck squamous cell carcinoma. The GTVentire was cropped by different margins to define the rim and the corresponding core sub-volumes of the tumour. Subsequently, the best performing tumour rim sub-volume was extended into surrounding tissue with different margins. Radiomic risk models were developed and validated using a retrospective cohort consisting of 291 patients in one of the six Partner Sites of the German Cancer Consortium Radiation Oncology Group treated between 2005 and 2013. The validation concordance index (C-index) averaged over all applied learning algorithms and feature selection methods using the GTVentire achieved a moderate prognostic performance for loco-regional tumour control (C-index: 0.61 ± 0.04 (mean ± std)). The models based on the 5 mm tumour rim and on the 3 mm extended rim sub-volume showed higher median performances (C-index: 0.65 ± 0.02 and 0.64 ± 0.05, respectively), while models based on the corresponding tumour core volumes performed less (C-index: 0.59 ± 0.01). The difference in C-index between the 5 mm tumour rim and the corresponding core volume showed a statistical trend (p = 0.10). After additional prospective validation, the consideration of tumour sub-volumes may be a promising way to improve prognostic radiomic risk models.
Background: To perform a comprehensive study on the relationship between vitamin D metabolism and the response to interferon-α-based therapy of chronic hepatitis C.
Methodology/Principal Findings: Associations between a functionally relevant polymorphism in the gene encoding the vitamin D 1α-hydroxylase (CYP27B1-1260 rs10877012) and the response to treatment with pegylated interferon-α (PEG-IFN-α) and ribavirin were determined in 701 patients with chronic hepatitis C. In addition, associations between serum concentrations of 25-hydroxyvitamin D3 (25[OH]D3) and treatment outcome were analysed. CYP27B1-1260 rs10877012 was found to be an independent predictor of sustained virologic response (SVR) in patients with poor-response IL28B genotypes (15% difference in SVR for rs10877012 genotype AA vs. CC, p = 0.02, OR = 1.52, 95% CI = 1.061–2.188), but not in patients with favourable IL28B genotype. Patients with chronic hepatitis C showed a high prevalence of vitamin D insufficiency (25[OH]D3<20 ng/mL) during all seasons, but 25(OH)D3 serum levels were not associated with treatment outcome.
Conclusions/Significance: Our study suggests a role of bioactive vitamin D (1,25[OH]2D3, calcitriol) in the response to treatment of chronic hepatitis C. However, serum concentration of the calcitriol precursor 25(OH)D3 is not a suitable predictor of treatment outcome.
Background: Vitamin D insufficiency has been associated with the occurrence of various types of cancer, but causal relationships remain elusive. We therefore aimed to determine the relationship between genetic determinants of vitamin D serum levels and the risk of developing hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC).
Methodology/Principal Findings: Associations between CYP2R1, GC, and DHCR7 genotypes that are determinants of reduced 25-hydroxyvitamin D (25[OH]D3) serum levels and the risk of HCV-related HCC development were investigated for 1279 chronic hepatitis C patients with HCC and 4325 without HCC, respectively. The well-known associations between CYP2R1 (rs1993116, rs10741657), GC (rs2282679), and DHCR7 (rs7944926, rs12785878) genotypes and 25(OH)D3 serum levels were also apparent in patients with chronic hepatitis C. The same genotypes of these single nucleotide polymorphisms (SNPs) that are associated with reduced 25(OH)D3 serum levels were found to be associated with HCV-related HCC (P = 0.07 [OR = 1.13, 95% CI = 0.99–1.28] for CYP2R1, P = 0.007 [OR = 1.56, 95% CI = 1.12–2.15] for GC, P = 0.003 [OR = 1.42, 95% CI = 1.13–1.78] for DHCR7; ORs for risk genotypes). In contrast, no association between these genetic variations and liver fibrosis progression rate (P>0.2 for each SNP) or outcome of standard therapy with pegylated interferon-α and ribavirin (P>0.2 for each SNP) was observed, suggesting a specific influence of the genetic determinants of 25(OH)D3 serum levels on hepatocarcinogenesis.
Conclusions/Significance: Our data suggest a relatively weak but functionally relevant role for vitamin D in the prevention of HCV-related hepatocarcinogenesis.
Background: IL28B gene polymorphism is the best baseline predictor of response to interferon alfa-based antiviral therapies in chronic hepatitis C. Recently, a new IFN-L4 polymorphism was identified as first potential functional variant for induction of IL28B expression. Individualization of interferon alfa-based therapies based on a combination of IL28B/IFN-L4 polymorphisms may help to optimize virologic outcome and economic resources.
Methods: Optimization of treatment outcome prediction was assessed by combination of different IL28B and IFN-L4 polymorphisms in patients with chronic HCV genotype 1 (n = 385), 2/3 (n = 267), and 4 (n = 220) infection treated with pegylated interferon alfa (PEG-IFN) and ribavirin with (n = 79) or without telaprevir. Healthy people from Germany (n = 283) and Egypt (n = 96) served as controls.
Results: Frequencies of beneficial IL28B rs12979860 C/C genotypes were lower in HCV genotype 1/4 infected patients in comparison to controls (20–35% vs. 46–47%) this was also true for ss469415590 TT/TT (20–35% vs. 45–47%). Single interferon-lambda SNPs (rs12979860, rs8099917, ss469415590) correlated with sustained virologic response (SVR) in genotype 1, 3, and 4 infected patients while no association was observed for genotype 2. Interestingly, in genotype 3 infected patients, best SVR prediction was based on IFN-L4 genotype. Prediction of SVR with high accuracy (71–96%) was possible in genotype 1, 2, 3 and 4 infected patients who received PEG-IFN/ribavirin combination therapy by selection of beneficial IL28B rs12979860 C/C and/or ss469415590 TT/TT genotypes (p<0.001). For triple therapy with first generation protease inhibitors (PIs) (boceprevir, telaprevir) prediction of high SVR (90%) rates was based on the presence of at least one beneficial genotype of the 3 IFN-lambda SNPs.
Conclusion: IFN-L4 seems to be the best single predictor of SVR in genotype 3 infected patients. For optimized prediction of SVR by treatment with dual combination or first generation PI triple therapies, grouping of interferon-lambda haplotypes may be helpful with positive predictive values of 71–96%.
A wide variety of enzymatic pathways that produce specialized metabolites in bacteria, fungi and plants are known to be encoded in biosynthetic gene clusters. Information about these clusters, pathways and metabolites is currently dispersed throughout the literature, making it difficult to exploit. To facilitate consistent and systematic deposition and retrieval of data on biosynthetic gene clusters, we propose the Minimum Information about a Biosynthetic Gene cluster (MIBiG) data standard.
Children’s and adolescents’ lives drastically changed during COVID lockdowns worldwide. To compare accident- and injury-related admissions to pediatric intensive care units (PICU) during the first German COVID lockdown with previous years, we conducted a retrospective multicenter study among 37 PICUs (21.5% of German PICU capacities). A total of 1444 admissions after accidents or injuries during the first lockdown period and matched periods of 2017–2019 were reported and standardized morbidity ratios (SMR) were calculated. Total PICU admissions due to accidents/injuries declined from an average of 366 to 346 (SMR 0.95 (CI 0.85–1.05)). Admissions with trauma increased from 196 to 212 (1.07 (0.93–1.23). Traffic accidents and school/kindergarten accidents decreased (0.77 (0.57–1.02 and 0.26 (0.05–0.75)), whereas household and leisure accidents increased (1.33 (1.06–1.66) and 1.34 (1.06–1.67)). Less neurosurgeries and more visceral surgeries were performed (0.69 (0.38–1.16) and 2.09 (1.19–3.39)). Non-accidental non-suicidal injuries declined (0.73 (0.42–1.17)). Suicide attempts increased in adolescent boys (1.38 (0.51–3.02)), but decreased in adolescent girls (0.56 (0.32–0.79)). In summary, changed trauma mechanisms entailed different surgeries compared to previous years. We found no evidence for an increase in child abuse cases requiring intensive care. The increase in suicide attempts among boys demands investigation.